Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

Annals of Internal Medicine

Volumn 128, Issue 12 PART 2, 1998, Pages 1079-1100

  Fauci, A S ^a   Bartlett, J G ^a   Goosby, E P ^a   Smith, M D ^a   Kaiser, H J ^a   Chang, S W ^a   Anderson, J ^a   Armstead, R ^a   Baker, A C ^a   Barr, D ^a   Bozzette, S ^a   Cox, S ^a   Delaney, M ^a   Gordin, F ^a   Greaves, W ^a   Harrington, M ^a   Henning, J J ^a   Hirsch, M S ^a   Jacobs, J ^a   Marlink, R ^a   Maxwell, C ^a   Mellors, J W ^a   Nash, D B ^a   Perryman, S ^a   Schooley, R T ^a   Sherer, R ^a   Spector, S A ^a   Torres, G ^a   Volberding, P ^a   Brady, B A ^a   Daniels, E M ^a   Feigal, D ^a   Feinberg, M ^a   Gayle, H D ^a   Graydon, T R ^a   Kaplan, J ^a   Macher, A ^a   Martin, R F ^a   Masur, H ^a   Mofenson, L ^a   Murray, J ^a   O'Neill, J ^a   Perez, L C ^a   Riseberg, R ^a   Shekar, S ^a   Stanley, S K ^a   Whitescarver, J ^a   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC AGENT; DELAVIRDINE; DIDANOSINE; ERGOT ALKALOID; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; CLINICAL PRACTICE; CLINICAL TRIAL; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LIVER TOXICITY; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MYALGIA; NEPHROLITHIASIS; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; VIRUS LOAD;

EID: 14444283113     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-12_part_2-199806151-00003     Document Type: Review

References (45)

1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1997;46(RR-12):1-46.
2. Perelson A, Essunger Y, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-91.
3. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165:352-63.
4. Carpenter C, Fischl M, Hammer S, et al. Updated recommendations of the International AIDS Society Panel - USA Panel. JAMA. 1997;277:1962-9.
5. Raboud J, Montaner J, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis. 1996;174:191-4.
6. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-17).
7. Fischl M, Richman D, Grieco M, et al. The efficacy of azidothymidine in the treatment of patients with AIDS and AIDS-related complex: a double blind, placebo controlled trial. N Engl J Med. 1987;317:185-91.
8. Fischl M, Richman D, Hansen H, et al. The safety and efficacy of zidovudine in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 infection: a double blind, placebo controlled trial. Ann Intern Med. 1990;112:727-37.
9. Volberding P, Lagakos S, Koch M, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990; 322:941-9.
10. Volberding P, Lagakos S, Grimes J, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437-42.
11. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-90.
12. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126: 946-54.
13. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. AIDS Clinical Trials Group 320 Study Section. N Engl J Med. 1997;337:725-33.
14. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
15. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:1019-30.
16. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA. 1998;279:930-7.
17. Bartlett J. Protease inhibitors for HIV infection. Ann Intern Med. 1996;124: 1086-8.
18. + T-cell counts in HIV-infected patients. Ann Intern Med. 1996;124:1039-50.
19. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-9.
20. Staszewski S, Loveday C, Picazo J, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA. 1996;276:111-7.
21. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995; 171:1411-9.
22. Keulen W, Back N, van Wijk A, et al. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutalional bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1997;71: 3346-50.
23. Dube M, Johnson D, Currier J, et al. Protease inhibitor-associated hyperglycaemia [Letter]. Lancet. 1997;350:713-4.
24. Visnegarwala F, Krause K, Musher D. Severe diabetes associated with protease inhibitor therapy [Letter]. Ann Intern Med. 1997;127:947.
25. Eastone J, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor [Letter]. Ann Intern Med. 1997;127:948.
26. Clinical update - impact of HIV protease inhibitors on the treatment of HIV infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep. 1996;45:921-5.
27. Niu M, Stein D, Schnittman S. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993;168:1490-501.
28. Schacker T, Collier A, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64.
29. Kinloch-de Loes S, de Saussure P, Saurat J, et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993;17:59-65.
30. Tindall B, Cooper D. Primary HIV infection: host responses and intervention strategies. AIDS. 1991;5:1-14.
31. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175:1051-5.
32. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996;45:468-80.
33. Hoen B, Harzic M, Fleury H, et al. ANRS053 trial of zidovudine, lamivudine, and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:107.
34. Tamalet C, Poizot Martin I, LaFeuillade A, et al. Viral load and genotypic resistance pattern in HIV-1 infected patients treated by a triple combination therapy including nucleoside and protease inhibitors initiated at primary infection [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC, 22-26 January, 1997:174.
35. Perrin L, Markowitz M, Calandra G, et al. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [Abstract]. In Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:108.
36. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997;176:478-89.
37. Hanson C, Cooper E, Antonelli T, et al. Lack of tumors in infants with perinatal HIV exposure and fetal/neonatal exposure to zidovudine [Abstract]. In: Proceedings of the National Conference on Women and HIV, Pasadena, CA, 4-7 May 1997:152.
38. Pregnancy outcomes following systemic prenatal acyclovir exposure - June 1, 1984-June 30, 1993. MMWR Morb Mortal Wkly Rep. 1993;42:806-9.
39. O'Sullivan M, Boyer P, Scott G, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group Study (protocol 082). Am J Obstet Gynecol. 1993;168:1510-6.
40. Moodley J, Moodley D, Pillay K, et al. Antiviral effect of lamivudine alone and in combination with zidovudine in HIV-infected pregnant women [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, 22-26 January 1997:176.
41. Sandberg J, Slikker W. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides. FASEB J. 1995;9:1157-63.
42. FDA Public Health Advisory. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). JAMA. 1997;278:379.
43. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant females infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47(RR-2).
44. Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus from mother to infant. N Engl J Med. 1996;335:1621-9.
45. Eastman P, Shapiro D, Coombs R, et al. Maternal genotypic ZDV resistance and failure of ZDV therapy to prevent mother-child transmission [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:160.